ライフサイエンスコーパス: plasmapheresis

1 s, 3 deceased), 21 of whom had pretransplant plasmapheresis.

2 ia purpura, and recovered after therapy with plasmapheresis.

3 nsplant and were treated with eculizumab +/- plasmapheresis.

4 aving metalloprotease by plasma infusion and plasmapheresis.

5 may respond to intravenous immunoglobulin or plasmapheresis.

6 espite treatment with fresh-frozen plasma or plasmapheresis.

7 no deaths among the 13 patients who received plasmapheresis.

8 ofile of IVIg would appear to be superior to plasmapheresis.

9 lication of HIV infection and may respond to plasmapheresis.

10 sed (one of five), and one of five underwent plasmapheresis.

11 phosphamide, intravenous immunoglobulins, or plasmapheresis.

12 n system, the Haemonetics PCS2, was used for plasmapheresis.

13 ration of intravenous immunoglobulins and/or plasmapheresis.

14 ith similar death-censored graft survival to plasmapheresis.

15 imab dose and 4 bortezomib doses preceded by plasmapheresis.

16 ectomy plus eculizumab (n=5), in addition to plasmapheresis.

17 bserved after rituximab; no patient required plasmapheresis.

18 , mechanical ventilation, and/or therapeutic plasmapheresis.

19 sttransplant and treated with eculizumab +/- plasmapheresis.

20 d retinopathy improved in all patients after plasmapheresis.

21 inal vein by laser Doppler, before and after plasmapheresis.

22 requiring thymoglobulin, IVIg, rituximab, or plasmapheresis.

23 Systemic therapies included plasmapheresis (18), chemotherapy (30), blood transfusio

24 ravenous immune globulin, 3 of 4 treated and plasmapheresis, 3 of 4 treated).

25 lasmapheresis than among those who underwent plasmapheresis (50% compared with 24%; P < 0.05).

26 Ten patients received plasmapheresis, 6 eculizumab, and 7 a combination of bot

27 failure, we investigated the application of plasmapheresis, a procedure involving the replacement of

28 oaches involving intravenous immunoglobulin/ plasmapheresis administered early in pregnancy most effe

29 llowed by a 2-week cycle on days 1-4-8-11 of plasmapheresis and 1.3 mg/m(2) bortezomib; then 0.5 mg/k

30 eracute rejection protocol applied including plasmapheresis and antithymocyte globulin treatment as w

31 essfully reversed with the implementation of plasmapheresis and cessation of clopidogrel and cyclospo

32 tor for severe PGD and could be treated with plasmapheresis and complement blockade.

33 nimally beneficial, but after treatment with plasmapheresis and corticosteroids, she was still asympt

34 Past protocols to desensitize patients using plasmapheresis and cyclophosphamide have not been broadl

35 We conclude that plasmapheresis and heme-albumin are of benefit in EPP co

36 ful treatment of the patient with additional plasmapheresis and heme-albumin with improvement of hepa

37 Treatment with plasmapheresis and high-dose corticosteroids may be effe

38 ted a patient with EPP who was improved with plasmapheresis and i.v. heme-albumin before OLT.

39 techniques such as intravenous immunoglobin, plasmapheresis and immuno-adsorption.

40 ed with improved clinical presentation after plasmapheresis and immunosuppressive treatments.

41 Other options include plasmapheresis and intravenous immunoglobulin (IVIg), co

42 Perioperative treatment with plasmapheresis and intravenous immunoglobulin (IVIG), co

43 Both plasmapheresis and intravenous immunoglobulin may be emp

44 gated whether cyclophosphamide combined with plasmapheresis and intravenous immunoglobulins is an opt

45 Other therapies included plasmapheresis and IVIg (64%), with 4 patients also rece

46 significantly higher PRA, and received more plasmapheresis and IVIG at the time of transplant.

47 -blood compatible columns, double-filtration plasmapheresis and lipoprotein (a)-apheresis.

48 Plasmapheresis and low-dose CMV-Ig combined with traditi

49 During this time, experience with both plasmapheresis and renal replacement therapy has become

50 Days 2-4: daily plasmapheresis and replacement of the shed plasma with 6

51 f bortezomib (1.3 mg/m(2)) over 2 weeks with plasmapheresis and rituximab.

52 cluded in a protocol involving pretransplant plasmapheresis and splenectomy at the time of transplant

53 Plasmapheresis and tacrolimus-mycophenolate mofetil resc

54 Plasmapheresis and the addition of cyclophosphamide led

55 The patient responded dramatically to plasmapheresis and the addition of high-dose corticoster

56 We used a protocol that included plasmapheresis and the administration of low-dose intrav

57 l antibodies and complement were depleted by plasmapheresis and the use of Gal alpha1-3Gal column ads

58 ter pretransplant conditioning regimen using plasmapheresis and/or intravenous immunoglobulin therapy

59 ) therapeutic interventions, e.g., dialysis, plasmapheresis, and (v) intensive care can be deployed t

60 reated with cyclophosphamide with or without plasmapheresis, and 2 of these grafts were lost from glo

61 and removal with intravenous immunoglobulin, plasmapheresis, and antibody therapy, newer strategies w

62 atients, for whom treatment with thymectomy, plasmapheresis, and conventional immunotherapeutic agent

63 acute AMR that did not respond to steroids, plasmapheresis, and intravenous immunoglobulin after his

64 levels and included thymoglobulin induction, plasmapheresis, and intravenous immunoglobulin in the hi

65 Immunomodulatory agents, such as steroids, plasmapheresis, and intravenous immunoglobulin, seem to

66 ol involved pretransplant immunosuppression, plasmapheresis, and low-dose intravenous immunoglobulin+

67 Bortezomib/plasmapheresis, and rituximab or obinutuzumab with intra

68 avenous heparin, intravenous gamma globulin, plasmapheresis, and/or antiproliferative agents.

69 s immunoglobulin, pulsed high-dose steroids, plasmapheresis, and/or rituximab.

70 Rapid diagnosis and treatment that includes plasmapheresis are critical for improved survival.

71 Intravenous immunoglobulin and plasmapheresis are used extensively but have limited eff

72 n we describe our center's experience with a plasmapheresis-based desensitization protocol for highly

73 des further evidence of the high efficacy of plasmapheresis-based desensitization protocols.

74 antigen antibodies (DSA) can be overcome by plasmapheresis-based strategies with some success in ren

75 In three patients who received plasmapheresis before bortezomib, plasmapheresis failed

76 sening require intravenous immunoglobulin or plasmapheresis before oral immunosuppressants start havi

77 ch case, the recipient had been treated with plasmapheresis before transplantation because of a posit

78 lowing two kinds of protein depletion: batch plasmapheresis (BP; n = 5) and thoracic duct drainage (T

79 Plasmapheresis can rapidly change the levels of pro-infl

80 Although plasmapheresis caused a similar reduction in alloreactiv

81 in 8 patients and were unchanged in 1 after plasmapheresis, chemotherapy, or both.

82 phosphamide, dapsone, mycophenolate mofetil, plasmapheresis, colchicine, hydroxychloroquine, intraven

83 us renal replacement therapy, in addition to plasmapheresis, corticosteroids, cyclophosphamide, and r

84 dose corticosteroids and, in some instances, plasmapheresis could prevent loss of high-contrast visio

85 Treatment for HR included plasmapheresis, cyclophosphamide, and rituximab.

86 as higher in several other groups, including plasmapheresis donors (34.0%), intravenous drug users (8

87 spital admission: PCR-confirmed convalescent plasmapheresis donors (n = 182), PCR-confirmed hospital

88 However, continuous plasmapheresis dramatically increased the tumor-to-backg

89 (corticosteroids/intravenous immunoglobulin/plasmapheresis) during pregnancy either for maternal MG

90 All patients received plasmapheresis every other day with intravenous immune g

91 o received plasmapheresis before bortezomib, plasmapheresis failed to reduce DSA.

92 esensitization, after desensitization (using plasmapheresis followed by 100 mg/kg intravenous immunog

93 ts treated with alternate-day, single-volume plasmapheresis followed by low-dose cytomegalovirus (CMV

94 to October of 1998, five patients underwent plasmapheresis for PNF after other causes of immediate a

95 ee patients were treated with eculizumab and plasmapheresis for recurrent aHUS after kidney transplan

96 versity Medical Center for consideration for plasmapheresis for the presumed essential type III cryog

97 rolimus was discontinued, and treatment with plasmapheresis, fresh frozen plasma, steroids, and OKT3

98 where liver failure was deemed irreversible, plasmapheresis functioned as a bridging therapy to manag

99 All recipients who underwent plasmapheresis had restoration of liver function.

100 ntravenous immunoglobulin is increasing, but plasmapheresis has not been shown to be of benefit.

101 Intravenous heme and plasmapheresis have been proposed but not previously rep

102 ng steroids, intravenous immunoglobulin, and plasmapheresis have shown limited efficacy in IgM monocl

103 The emergency treatment of DNS with combined plasmapheresis, HDIVig, and high-dose corticosteroids in

104 In spite of steroid treatment and plasmapheresis, his clinical status deteriorated rapidly

105 He was managed initially with plasmapheresis, hypertransfusion, and infusions of i.v.

106 ys after transplantation, which responded to plasmapheresis, i.v.IG, and rituximab.

107 efractory to aggressive treatment, including plasmapheresis, immunosuppression with prednisolone, and

108 ne to two cycles (1.3 mg/m(2) x 4 doses) and plasmapheresis in 2008 to remove HLA antibodies posttran

109 n 3, OKT3 for concurrent rejection in 3, and plasmapheresis in 5 patients.

110 Additionally, we achieved successful plasmapheresis in a sensitized mouse, significantly lowe

111 ulinemia treated successfully with long-term plasmapheresis in conjunction with thalidomide and dexam

112 The role of plasmapheresis in liver failure and hepatic coma remains

113 ally, this study highlights the potential of plasmapheresis in managing severe cases.

114 This report reviews the use of plasmapheresis in primary hepatic allograft nonfunction

115 s of action, the efficacy, and the safety of plasmapheresis in rheumatic diseases demonstrates that t

116 shown that early administration of IVIG and plasmapheresis in severe cases can reduce the need for m

117 After plasmapheresis in six patients with recurrences, the per

118 anisms that explain the efficacy of repeated plasmapheresis in this setting are suggested.

119 A trial of immunomodulation (plasmapheresis in two patients and intravenous immunoglo

120 either intravenous immunoglobulin (IVIg) or plasmapheresis, in conjunction with cyclophosphamide.

121 e 3 hemolytic uremic syndrome, not requiring plasmapheresis, in two patients (6%).

122 Perioperative plasmapheresis increased the risk for transfusion of pac

123 mplement has been treated by combinations of plasmapheresis, intravenous gamma-globulin and monoclona

124 mpatible recipients, and was reversible with plasmapheresis, intravenous immunoglobulin, and increasi

125 nti-human leukocyte antigen antibodies using plasmapheresis, intravenous immunoglobulin, and rituxima

126 All had received previous treatment with plasmapheresis, intravenous immunoglobulin, and rituxima

127 , and prednisone combined with pretransplant plasmapheresis, intravenous immunoglobulin, and splenect

128 ts treated with more than four pretransplant plasmapheresis/intravenous immunoglobulin (PP/IVIg) had

129 The immunosuppressive protocol consisted of plasmapheresis/intravenous immunoglobulin infusion befor

130 Plasmapheresis is a medical procedure that separates pla

131 fter kidney transplantation by rituximab and plasmapheresis is ambiguous.

132 Plasmapheresis is effective in reversing HVS-related ret

133 Plasmapheresis is known to reduce serum viscosity (SV) a

134 ole of corticosteroids, immune globulin, and plasmapheresis is uncertain.

135 Combinations that include plasmapheresis, IVIG, cyclophosphamide, and rituximab ha

136 , addition of mycophenolate mofetil (MMF) or plasmapheresis (L3); and anti-CD20 (Rituximab) (L4).

137 ine A, mycophenolate mofetil, gammaglobulin, plasmapheresis, LJP 394, flaxseed oil, bindarit, anti-CD

138 ied 38 patients from 3 centers (29 receiving plasmapheresis/low-dose intravenous immunoglobulin [IVIg

139 For patients undergoing plasmapheresis/low-dose IVIg, antibody titer reduction c

140 Patients' plasmapheresis material was tested for the presence of a

141 Although plasmapheresis may ameliorate acute allograft disease, s

142 The long-term use of plasmapheresis may be a well-tolerated treatment option

143 Plasmapheresis may have a more consistent response rate

144 It has been suggested that plasmapheresis may improve coagulopathy and prevent blee

145 ents treated with eculizumab (n = 11) and/or plasmapheresis (n = 13) during the acute phase of HUS ha

146 venous immunoglobulins (n = 71/74; 96%), and plasmapheresis (n = 17/74; 23%).

147 ytotoxic (CDC) crossmatch (XM) pretransplant plasmapheresis, nine had positive flow cytometric (FC) X

148 o halt the progression of CAPS, but repeated plasmapheresis not only halted the condition, but it led

149 this study was to investigate the effects of plasmapheresis on HVS-related retinopathy and retinal he

150 s/arm; range, 5-23), of which, four examined plasmapheresis (one suggested benefit) and one for immun

151 We did not rely on plasmapheresis or anti-A titer determinations.

152 teinuria that may remit after treatment with plasmapheresis or immunoadsorption.

153 C4d deposition was not treated with plasmapheresis or intravenous immunoglobulin and was not

154 Eighteen patients (78%) were treated with plasmapheresis or low-dose IVIg+rituximab; 11 (49%) with

155 medications as needed, and consideration of plasmapheresis or use of immunoadsorption column in seve

156 lowering serum suPAR concentrations through plasmapheresis, or by interfering with the suPAR-beta(3)

157 Plasmapheresis, or TPE, removes monoclonal antibodies, i

158 She responded to repeated plasmapheresis over 3 years.

159 in total plasma protein concentration after plasmapheresis (p < .05).

160 Plasmapheresis (PE) is an established form of therapeuti

161 apy was administered per package insert with plasmapheresis performed immediately before each bortezo

162 t regimens commonly include a combination of plasmapheresis (PL) and intravenous immunoglobulin (IVIG

163 Intravenous immunoglobulin and plasmapheresis (PLEX) have limited success due to antibo

164 The comparative efficacy of plasmapheresis (PLEX) vs immunoglobulin as maintenance t

165 Plasmapheresis (PP) and intravenous immunoglobulin (IVIg

166 t survival of patients with AHR treated with plasmapheresis (PP) and intravenous immunoglobulin (IVIG

167 This patient received one plasmapheresis (PP) and intravenous immunoglobulin (IVIg

168 Plasmapheresis (PP) has been shown to remove HLA- specif

169 Plasmapheresis (PP) has been used in the treatment of va

170 Predicting recurrence and response to plasmapheresis (PP) or other interventions remains probl

171 97+/-3% vs. 76+/-20%, P=NS) and after 3 IVIg/plasmapheresis (PP) treatments but lower among responder

172 nts with anti-A1 titers > or = 1:8 underwent plasmapheresis (PP).

173 been removal of donor-specific antibodies by plasmapheresis (PPH) in conjunction with intravenous imm

174 ansplant using an intravenous immunoglobulin/plasmapheresis preconditioning regimen with interleukin-

175 body-mediated rejection and graft loss using plasmapheresis preconditioning, low-dose intravenous imm

176 Apart from drastic measures such as extended plasmapheresis, pretargeting selectivity was neither sen

177 DSAs were removed with plasmapheresis pretransplant, and patients did not routi

178 These patients underwent two to five plasmapheresis procedures during which one plasma volume

179 Plasmapheresis provides an effective treatment option fo

180 groups underwent similar treatment including plasmapheresis, pulse steroids, IVIG, and rituximab (P =

181 antibody and a more intensive posttransplant plasmapheresis regiment aimed at maintaining low levels

182 All patients treated with bortezomib/plasmapheresis resulted in a primary DSA reduction of mo

183 Plasmapheresis resulted in significant reductions in ser

184 Treatment interventions included plasmapheresis, resulting in functional improvement: the

185 ata indicate that proteasome inhibitors plus plasmapheresis results in prolonged reduction of HLA ant

186 erapy (steroids, intravenous immunoglobulin, plasmapheresis), second-line immunotherapy (rituximab, c

187 A median (interquartile range) of 15 (10-23) plasmapheresis sessions was administered; 13 of the subj

188 polyvalent immunoglobulins +/- perioperative plasmapheresis sessions, according to DSA level, as well

189 Plasmapheresis should be considered for symptomatic hype

190 Repeated plasmapheresis should be considered in the most refracto

191 Plasmapheresis should be used for patients with symptoma

192 cannot give a simple answer to the question: plasmapheresis-take it or leave it?

193 , intravenous immunoglobulins, cyclosporine, plasmapheresis, thalidomide, cyclophosphamide, hemoperfu

194 her among patients who were not treated with plasmapheresis than among those who underwent plasmapher

195 Pretransplant the patients received plasmapheresis three times weekly for a planned maximum

196 It is postulated that perhaps plasmapheresis, through removal of cytokines or other me

197 Patients were treated with plasmapheresis, thymoglobulin/OKT3, and corticosteroids.

198 the failure of corticosteroid, rituximab and plasmapheresis to attenuate the rate of decline in allog

199 bbit (r) ATG can be used in combination with plasmapheresis to effectively treat antibody-mediated re

200 hours after revascularization and underwent plasmapheresis to obtain plasma with a high cTn concentr

201 recipient cross-match were desensitized with plasmapheresis to permit live donor (LD) transplantation

202 Attempts to deal with this problem have used plasmapheresis to remove antibodies or high-dose pooled

203 osed with atypical HUS (aHUS) and started on plasmapheresis, together with eculizumab.

204 ma IgM levels were measured before and after plasmapheresis treatment.

205 bulin cross-match-negative after one to five plasmapheresis treatments and underwent LD transplantati

206 a pretransplant conditioning regimen of four plasmapheresis treatments followed by intravenous immuno

207 An initial short course of 5 plasmapheresis treatments improved the patient's cutaneo

208 y-four patients had a median of 2 additional plasmapheresis treatments to reach the preoperative targ

209 nts with non-antigen-specific IA, additional plasmapheresis treatments were necessary for recipient d

210 x treatments with antigen-specific IA and 12 plasmapheresis treatments, one patient with a starting i

211 us immunoglobulin therapy, a 3-day course of plasmapheresis was administered.

212 Moreover, plasmapheresis was associated with an unacceptably high

213 Instead, plasmapheresis was associated with increases in DNAmGrim

214 Plasmapheresis was initiated to decrease the number of c

215 Once plasmapheresis was initiated, she required no further tr

216 versible hemolytic uremic syndrome requiring plasmapheresis was observed in one patient with NHL duri

217 Plasmapheresis was performed for severe cases (n = 10).

218 as the international normalized ratio (INR) Plasmapheresis was performed until the INR reached stabl

219 Plasmapheresis was planned for up to 3 months after LDLT

220 persistence of the woman's ulcers, intensive plasmapheresis was resumed and continued 3 to 4 times pe

221 re liver damage accompanied by coagulopathy, plasmapheresis was utilized to replace deficient clottin

222 Rejections requiring plasmapheresis were found only among patients with T-pos

223 hibitors, corticosteroids for rejection, and plasmapheresis were not associated with developing PJP.

224 ombined with other agents (intravenous IG or plasmapheresis) were selected as a first-line therapy by

225 he fifth postoperative day and completion of plasmapheresis when a repeated retrospective cross-match

226 (intravenous immunoglobulin, steroids and/or plasmapheresis), whereas the four patients who later wen

227 eaths occurring in patients not treated with plasmapheresis, whereas there were no deaths among the 1

228 esistant to steroids, cyclophos-phamide, and plasmapheresis who responded to the addition of anti-CD2

229 ntinuation of FK506, anticoagulation, and/or plasmapheresis with fresh-frozen plasma exchange, resolv

230 ipients continued to receive every other day plasmapheresis with intravenous immune globulin for the

231 of a desensitization protocol also involving plasmapheresis) with specimens obtained in 91 patients w

232 He was treated with steroids and plasmapheresis, with mild improvement in vision.

233 This study aimed to assess whether plasmapheresis without volume replacement with young pla

234 the offending antibody may be possible with plasmapheresis, without the expectation for significant